Shutterstock / Tish1
The slowdown in total spending on prescriptions in Canada masks dramatic changes in the pharmaceutical sector. Beneath the calm surface lies a rapid decline in spending on widely used medicines to treat relatively common conditions, and even more dramatic increases in spending on medicines used by relatively few people who suffer from serious conditions.
It is Canada's challenge to ensure this country is attractive to those who are making the decisions on where to invest their dollars for the discovery and development of innovative new treatments.
So while critics try to dismiss stronger IP as nothing more than a technique to pad the bottom line of a faceless corporation, for millions of Canadians it could be a matter of life and breath.